VEGFA and non-small cell lung carcinoma: Many antiangiogenic agents targeting the VEGF-A/VEGFR2 signaling pathway, such as bevacizumab, ramucirumab and nintedanib, are currently used for the treatment of NSCLC patients or are in development [6–8].